EcoDrugPlus

Opioid Receptor Mu 1

Ensembl ID : ENSUMAG00000013465
Gene Symbol: OPRM1
2 Cross references
214 Possible Orthologues:

Opioid Related Nociceptin Receptor 1

Ensembl ID : ENSUMAG00000021537
Gene Symbol: OPRL1
4 Cross references
199 Possible Orthologues:

Pancreatic Alpha-Amylase-Like

Ensembl ID : ENSUMAG00000007706
Gene Symbol: LOC103669312
3 Cross references
212 Possible Orthologues:

Pancreatic Alpha-Amylase-Like

Ensembl ID : ENSUMAG00000007724
Gene Symbol: LOC103669314
3 Cross references
212 Possible Orthologues:

Pancreatic Lipase

Ensembl ID : ENSUMAG00000002702
Gene Symbol: PNLIP
4 Cross references
300 Possible Orthologues:

Peroxisome Proliferator Activated Receptor Alpha

Ensembl ID : ENSUMAG00000019461
Gene Symbol: PPARA
4 Cross references
453 Possible Orthologues:

Peroxisome Proliferator Activated Receptor Delta

Ensembl ID : ENSUMAG00000010402
Gene Symbol: PPARD
4 Cross references
418 Possible Orthologues:

Peroxisome Proliferator Activated Receptor Gamma

Ensembl ID : ENSUMAG00000017617
Gene Symbol: PPARG
4 Cross references
405 Possible Orthologues:

Phosphatidylinositol-4,5-Bisphosphate 3-Kinase Catalytic Subunit Alpha

Ensembl ID : ENSUMAG00000007616
Gene Symbol: PIK3CA
4 Cross references
275 Possible Orthologues:

Phosphatidylinositol-4,5-Bisphosphate 3-Kinase Catalytic Subunit Beta

Ensembl ID : ENSUMAG00000014852
Gene Symbol: PIK3CB
4 Cross references
214 Possible Orthologues:

Phosphatidylinositol-4,5-Bisphosphate 3-Kinase Catalytic Subunit Delta

Ensembl ID : ENSUMAG00000024059
Gene Symbol: PIK3CD
4 Cross references
213 Possible Orthologues:

Phosphatidylinositol-4,5-Bisphosphate 3-Kinase Catalytic Subunit Gamma

Ensembl ID : ENSUMAG00000018277
Gene Symbol: PIK3CG
4 Cross references
213 Possible Orthologues:

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).